Spero therapeutics announces special protocol assessment agreement with fda for phase 3 pivot-po trial of tebipenem hbr

Phase 3 pivot-po trial is expected to begin with first patient, first visit in 4q 2023
SPRO Ratings Summary
SPRO Quant Ranking